Aktie A2DQCR KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Kubota Pharmaceutical Holdings Co., Ltd.

Aktien

A2DQCR

JP3266500002

4596

Markt geschlossen - Japan Exchange
Andere Börsenplätze
 08:00:00 01.05.2024 		% 5 Tage % 1. Jan.
70 JPY 0.00% Intraday Chart für Kubota Pharmaceutical Holdings Co., Ltd. 0.00% -12.50%
22.03. Kubota Pharmaceutical passt Finanzergebnisse für 2023 nach Neubewertung an MT
14.02. Kubota Pharmaceutical Holdings Co., Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Kubota Pharmaceutical Adjusts 2023 Financial Results Following Reevaluation
Kubota Pharmaceutical Holdings Co., Ltd. Restates Consolidated and Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2023
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Kubota Pharmaceutical Group Launches Its Unique Kubota Glass Technology Aiming to Revolutionize Myopia Management
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022
Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive ¥3.1 million in funding from Barclays Bank PLC, Investment Arm
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022
Kubota Pharmaceutical Holdings Co., Ltd. Announces Database Lock for Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease and Expected Release of Top-Line Results in August 2022
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2021
Kubota Pharmaceutical : Summary of Financial Results for the second quarter 2021
Kubota Pharmaceutical : Consolidated Financial Results for the Six Months Ended June 30, 2021(under IFRS)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DQCR Aktie
  4. Nachrichten Kubota Pharmaceutical Holdings Co., Ltd.
  5. Andere Sprachen